Compare IIF & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIF | IPSC |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.5M | 189.7M |
| IPO Year | N/A | 2021 |
| Metric | IIF | IPSC |
|---|---|---|
| Price | $23.50 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 41.9K | ★ 919.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | ★ 29.07 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $6,589,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.97 |
| Revenue Growth | N/A | ★ 194.81 |
| 52 Week Low | $22.20 | $0.34 |
| 52 Week High | $28.37 | $2.71 |
| Indicator | IIF | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 62.66 |
| Support Level | $23.12 | $0.49 |
| Resistance Level | $27.70 | $2.71 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 19.71 | 81.08 |
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.